Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
Go back to Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study| (NASDAQ: PULM) | Delayed: 1.40 +0.02 (1.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.38 | 52 Week High | $5.56 | |||
| Open | $1.41 | 52 Week Low | $0.76 | |||
| Day High | $1.45 | P/E | N/A | |||
| Day Low | $1.38 | EPS | $0.00 | |||
| Volume | 23,652 | |||||
